Rhenman & Partners Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.32M	Sell	8,050 -16,000	-67%	-$8.2M	0.41%	77
2026 Q1	$12.6M	Buy	24,050 +4,500	+23%	+$2.15M	1.55%	21
2025 Q4	$11.4M	Buy	19,550 +1,300	+7%	+$664K	1.06%	37
2025 Q3	$8.37M	Buy	+18,250	New	+$6.81M	0.93%	40
2024 Q4	–	Sell	-15,300	Closed	-$3.25M	–	97
2024 Q3	$3.25M	Sell	15,300 -11,200	-42%	-$2.87M	0.26%	79
2024 Q2	$7.42M	Sell	26,500 -10,000	-27%	-$2.38M	0.71%	41
2024 Q1	$9.75M	Buy	36,500 +14,000	+62%	+$3.3M	0.92%	39
2023 Q4	$5.21M	Buy	+22,500	New	+$3.94M	0.52%	59
2019 Q4	–	Sell	-30,000	Closed	-$2.59M	–	98
2019 Q3	$2.59M	Sell	30,000 -7,225	-19%	-$678K	0.32%	71
2019 Q2	$3.9M	Buy	37,225 +10,000	+37%	+$1.07M	0.43%	62
2019 Q1	$3.41M	Buy	+27,225	New	+$3.38M	0.4%	64
2014 Q1	–	Sell	-2,857	Closed	-$524K	–	97
2013 Q4	$524K	Buy	+2,857	New	+$523K	0.21%	81

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rhenman & Partners Asset Management's MDGL Position: Q2 2026 in Review

Rhenman & Partners Asset Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 67% in Q2 2026, selling an estimated $8.2M and leaving 8,050 shares worth $4.32M. The position accounts for 0.41% of the portfolio, ranked #77.

Rhenman & Partners Asset Management first reported a position in MDGL in Q4 2013 and has held it in 12 quarters since. The position peaked at $12.6M in Q1 2026. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Rhenman & Partners Asset Management held 8,050 shares of Madrigal Pharmaceuticals worth $4.32M as of Q2 2026.
Rhenman & Partners Asset Management sold 16,000 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $8.2M.
Madrigal Pharmaceuticals made up 0.41% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #77 holding.
Rhenman & Partners Asset Management first reported a position in Madrigal Pharmaceuticals in Q4 2013 and has held it in 12 quarters since.
Rhenman & Partners Asset Management's Madrigal Pharmaceuticals position peaked at $12.6M in Q1 2026.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.